These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

381 related articles for article (PubMed ID: 19737224)

  • 21. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The S492R EGFR ectodomain mutation is never detected in KRAS wild-type colorectal carcinoma before exposure to EGFR monoclonal antibodies.
    Esposito C; Rachiglio AM; La Porta ML; Sacco A; Roma C; Iannaccone A; Tatangelo F; Forgione L; Pasquale R; Barbaro A; Botti G; Ciardiello F; Normanno N
    Cancer Biol Ther; 2013 Dec; 14(12):1143-6. PubMed ID: 24025416
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
    Ng K; Zhu AX
    Crit Rev Oncol Hematol; 2008 Jan; 65(1):8-20. PubMed ID: 18006328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overview of monoclonal antibodies and small molecules targeting the epidermal growth factor receptor pathway in colorectal cancer.
    Snyder LC; Astsaturov I; Weiner LM
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S71-80. PubMed ID: 16336752
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cetuximab: appraisal of a novel drug against colorectal cancer.
    Hildebrandt B; le Coutre P; Nicolaou A; Köble K; Riess H; Dörken B
    Recent Results Cancer Res; 2007; 176():135-43. PubMed ID: 17607921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications for KRAS status and EGFR-targeted therapies in metastatic CRC.
    Normanno N; Tejpar S; Morgillo F; De Luca A; Van Cutsem E; Ciardiello F
    Nat Rev Clin Oncol; 2009 Sep; 6(9):519-27. PubMed ID: 19636327
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broad RTK-targeted therapy overcomes molecular heterogeneity-driven resistance to cetuximab via vectored immunoprophylaxis in colorectal cancer.
    Hu S; Dai H; Li T; Tang Y; Fu W; Yuan Q; Wang F; Lv G; Lv Y; Fan X; Zhang S; Jin R; Shen Y; Lin F; Ye X; Ding M; Yang Y; Lei C
    Cancer Lett; 2016 Nov; 382(1):32-43. PubMed ID: 27569653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Panitumumab in patients with KRAS wild-type colorectal cancer after progression on cetuximab.
    Wadlow RC; Hezel AF; Abrams TA; Blaszkowsky LS; Fuchs CS; Kulke MH; Kwak EL; Meyerhardt JA; Ryan DP; Szymonifka J; Wolpin BM; Zhu AX; Clark JW
    Oncologist; 2012; 17(1):14. PubMed ID: 22210091
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
    Watkins D; Cunningham D
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S47-52. PubMed ID: 18021487
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
    Gainet M; Guardiola E; Dufresne A; Pivot X
    Cancer Radiother; 2003 Jun; 7(3):195-9. PubMed ID: 12834777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized, phase II study of the insulin-like growth factor-1 receptor inhibitor IMC-A12, with or without cetuximab, in patients with cetuximab- or panitumumab-refractory metastatic colorectal cancer.
    Reidy DL; Vakiani E; Fakih MG; Saif MW; Hecht JR; Goodman-Davis N; Hollywood E; Shia J; Schwartz J; Chandrawansa K; Dontabhaktuni A; Youssoufian H; Solit DB; Saltz LB
    J Clin Oncol; 2010 Sep; 28(27):4240-6. PubMed ID: 20713879
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cetuximab.
    Goldberg RM
    Nat Rev Drug Discov; 2005 May; Suppl():S10-1. PubMed ID: 15962524
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Panitumumab a novel drug in cancer treatment.
    Cartenì G; Fiorentino R; Vecchione L; Chiurazzi B; Battista C
    Ann Oncol; 2007 Jun; 18 Suppl 6():vi16-21. PubMed ID: 17591813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.
    Gialeli Ch; Kletsas D; Mavroudis D; Kalofonos HP; Tzanakakis GN; Karamanos NK
    Curr Med Chem; 2009; 16(29):3797-804. PubMed ID: 19747140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Infectious complications in cancer patients treated with anti-EGFR monoclonal antibodies cetuximab and panitumumab: a systematic review and meta-analysis.
    Funakoshi T; Suzuki M; Tamura K
    Cancer Treat Rev; 2014 Dec; 40(10):1221-9. PubMed ID: 25288497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
    Brockstein B; Lacouture M; Agulnik M
    J Natl Compr Canc Netw; 2008 Aug; 6(7):696-706. PubMed ID: 18691458
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
    Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
    J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.